Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • apoptosis, cancer, Cannabinoid receptor 1 (CB1), Cannabinoid receptor 2 (CB2), Cannabinoid/s, lymphoma, xenograft
Loading...

Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation

Endogenous and synthetic cannabinoids exert antiproliferative and proapoptotic effects in various types of cancer and in mantle cell lymphoma (MCL). In this study, we evaluated the expression of cannabinoid receptors type 1 and type 2 (CB1 and CB2) in nonHodgkin lymphomas of B cell type (n 5 62). A majority of the lymphomas expressed higher mRNA levels of CB1 and/or CB2 as compared to reactive lymphoid tissue. With the exception of MCL, which uniformly overexpresses both CB1 and CB2, the levels of cannabinoid receptors within other lymphoma entities were highly variable, ranging from 0.1 to 224 times the expression in reactive lymph nodes. Low...
Read More

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma

Background: Neuroblastoma (nbl) is one of the most common solid cancers in children. Prognosis in advanced nbl is still poor despite aggressive multimodality therapy. Furthermore, survivors experience severe long-term multi-organ sequelae. Hence, the identification of new therapeutic strategies is of utmost importance. Cannabinoids and their derivatives have been used for years in folk medicine and later in the field of palliative care. Recently, they were found to show pharmacologic activity in cancer, including cytostatic, apoptotic, and antiangiogenic effects. Methods: We investigated, in vitro and in vivo, the anti-nbl effect of the most active compounds in Cannabis, Δ9-tetrahydrocannabinol (thc) and cannabidiol (cbd). We set out...
Read More

Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent

Aim—We hypothesized that the anticancer activity of cannabinoids was linked to induction of phosphatases. Materials and Methods—The effects of cannabidiol (CBD) and the synthetic cannabinoid WIN-55,212 (WIN) on LNCaP (prostate) and SW480 (colon) cancer cell proliferation were determined by cell counting; apoptosis was determined by cleavage of poly(ADP)ribose polymerase (PARP) and caspase-3 (Western blots); and phosphatase mRNAs were determined by real-time PCR. The role of phosphatases and cannabinoid receptors in mediating CBD- and WINinduced apoptosis was determined by inhibition and receptor knockdown. Results—CBD and WIN inhibited LNCaP and SW480 cell growth and induced mRNA expression of several phosphatases, and the phosphatase inhibitor sodium orthovanadate...
Read More

Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent

Introduction: Cannabinoid compounds, both nonspecific as well as agonists selective for either cannabinoid receptor 1 (CB1 ) or cannabinoid receptor 2 (CB2 ), have been shown to modulate the tumor microenvironment by inducing apoptosis in tumor cells in several model systems. The mechanism of this modulation remains only partially delineated, and activity induced via the CB1 and CB2 receptors may be distinct despite significant sequence homology and structural similarity of ligands. Methods: The CB2 -selective agonist JWH-015 was used to investigate mechanisms downstream of CB2 activation in mouse and human breast cancer cell lines in vitro and in a murine mammary tumor model. Results:...
Read More

Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells

Abstract Alzheimer's disease is widely held to be associated with oxidative stress due, in part, to the membrane action of beta-amyloid peptide aggregates. Here, we studied the effect of cannabidiol, a major non-psychoactive component of the marijuana plant (Cannabis sativa) on beta-amyloid peptide-induced toxicity in cultured rat pheocromocytoma PC12 cells. Following exposure of cells to beta-amyloid peptide (1 micro g/mL), a marked reduction in cell survival was observed. This effect was associated with increased reactive oxygen species (ROS) production and lipid peroxidation, as well as caspase 3 (a key enzyme in the apoptosis cell-signalling cascade) appearance, DNA fragmentation and increased intracellular calcium. Treatment of...
Read More

Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms

BACKGROUND AND PURPOSE Cannabinoid receptor activation induces prostate carcinoma cell (PCC) apoptosis, but cannabinoids other than D9 -tetrahydrocannabinol (THC), which lack potency at cannabinoid receptors, have not been investigated. Some of these compounds antagonize transient receptor potential melastatin type-8 (TRPM8) channels, the expression of which is necessary for androgen receptor (AR)-dependent PCC survival. EXPERIMENTAL APPROACH We tested pure cannabinoids and extracts from Cannabis strains enriched in particular cannabinoids (BDS), on AR-positive (LNCaP and 22RV1) and -negative (DU-145 and PC-3) cells, by evaluating cell viability (MTT test), cell cycle arrest and apoptosis induction, by FACS scans, caspase 3/7 assays, DNA fragmentation and TUNEL, and size...
Read More

Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas

To evaluate, through a systematic review of the literature, the antitumoral effects of cannabinoids on gliomas. Research included the following electronic databases: PUBMED, EMBASE, LILACS and The Cochrane Collaboration Controlled Trials Register. All published studies involving the antitumoral effects (cellular and molecular mechanisms) of cannabinoids were considered for this review. The bibliography search strategy included all publications of each of these databases until December 31, 2012. From 2,260 initially identified articles, 35 fulfilled the inclusion criteria for this review. All the studies included in this systematic review were experimental (in vivo and/or in vitro), except for one pilot clinical trial phase I/II involving humans....
Read More

The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells

Deregulation of cell survival pathways and resistance to apoptosis are widely accepted to be fundamental aspects of tumorigenesis. As in many tumours, the aberrant growth and survival of colorectal tumour cells is dependent upon a small number of highly activated signalling pathways, the inhibition of which elicits potent growth inhibitory or apoptotic responses in tumour cells. Accordingly, there is considerable interest in therapeutics that can modulate survival signalling pathways and target cancer cells for death. There is emerging evidence that cannabinoids, especially D9 -tetrahydrocannabinol (THC), may represent novel anticancer agents, due to their ability to regulate signalling pathways critical for cell growth and survival....
Read More

The endocannabinoid system and cancer: therapeutic implication

The endocannabinoid system is implicated in a variety of physiological and pathological conditions (inflammation, immunomodulation, analgesia, cancer and others). The main active ingredient of cannabis, D9 -tetrahydrocannabinol (D9 -THC), produces its effects through activation of CB1 and CB2 receptors. CB1 receptors are expressed at high levels in the central nervous system (CNS), whereas CB2 receptors are concentrated predominantly, although not exclusively, in cells of the immune system. Endocannabinoids are endogenous lipid-signalling molecules that are generated in the cell membrane from phospholipid precursors. The two best characterized endocannabinoids identified to date are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Here we review the relationship between the endocannabinoid...
Read More

The use of cannabinoids as anticancer agents

It is well-established that cannabinoids exert palliative effects on some cancer-associated symptoms. In addition evidences obtained during the last fifteen years support that these compounds can reduce tumor growth in animal models of cancer. Cannabinoids have been shown to activate an ER-stress related pathway that leads to the stimulation of autophagy-mediated cancer cell death. In addition, cannabinoids inhibit tumor angiogenesis and decrease cancer cell migration. The mechanisms of resistance to cannabinoid anticancer action as well as the possible strategies to develop cannabinoid-based combinational therapies to fight cancer have also started to be explored. In this review we will summarize these observations (that have already...
Read More
« Previous 1 2 3 Next »

REGISTER WITH RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • PO Box 15224, Colorado Springs, CO 80935
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2024 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer

Open the following in new tabs if you:

If you are already a user: Client Login

If you are not, then register: Client Registration

Once Logged in, click below to refresh the page.